TuisIONS • NASDAQ
add
Ionis Pharmaceuticals Inc
Vorige sluiting
$43,05
Dagwisseling
$40,74 - $42,87
Jaarwisseling
$23,95 - $50,37
Markkapitalisasie
6,54 mjd USD
Gemiddelde volume
2,07 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 452,05 m | 100,69% |
Bedryfskoste | 90,62 m | 39,18% |
Netto inkomste | 123,55 m | 286,45% |
Netto winsgrens | 27,33 | 192,90% |
Wins per aandeel | 0,85 | 452,98% |
EBITDA | 142,68 m | 326,46% |
Effektiewe belastingkoers | -0,02% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,29 mjd | 9,95% |
Totale bates | 2,99 mjd | 10,92% |
Totale aanspreeklikheid | 2,35 mjd | -3,05% |
Totale ekwiteit | 631,72 m | — |
Uitstaande aandele | 159,39 m | — |
Prys om te bespreek | 10,84 | — |
Opbrengs op bates | 12,06% | — |
Opbrengs op kapitaal | 13,82% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 123,55 m | 286,45% |
Kontant van bedrywe | 151,34 m | 226,24% |
Kontant van beleggings | -120,07 m | -292,26% |
Kontant van finansiering | 1,25 m | -51,23% |
Netto kontantverandering | 33,11 m | 160,32% |
Beskikbare kontantvloei | 98,52 m | 197,53% |
Meer oor
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra, and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Gestig
1989
Hoofkwartier
Webwerf
Werknemers
1 069
